Izraēla - angļu - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 37.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 50 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 120 mg - dimethyl fumarate - dimethyl fumarate taro is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - dimethyl fumarate - gastro resistant hard capsule - dimethyl fumarate 240 mg - dimethyl fumarate - dimethyl fumarate taro is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 125 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 250 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - deferasirox - dispersible tablets for oral suspension - deferasirox 500 mg - deferasirox - deferasirox taro is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox taro is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic]≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). lic is the preferred method of iron overload determination and should be used wherever available.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - triamcinolone acetonide - paste - triamcinolone acetonide 0.1 % - triamcinolone - triamcinolone - indicated for the adjunctive treatment and the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - cinacalcet as hydrochloride - film coated tablets - cinacalcet as hydrochloride 30 mg - cinacalcet - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy. cinacalcet taro may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma. reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Izraēla - angļu - Ministry of Health

taro international ltd, israel - cinacalcet as hydrochloride - film coated tablets - cinacalcet as hydrochloride 60 mg - cinacalcet - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy. cinacalcet taro may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma. reduction of hypercalcaemia in patients with: • parathyroid carcinoma. • primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.